LUVMyBirman
Well-known member
"Information' contained in the article is purely the opinion of the manufacturers and must be read and consumed as such".
St. Jude Medical Gains FDA Approval For Next-Generation Mechanical Heart Valve
ST. PAUL, Minn.--(BUSINESS WIRE)--March 5, 2002--St. Jude Medical, Inc. (NYSE:STJ) today announced it has received U.S. Food and Drug Administration (FDA) approval for the SJM Regent(TM)heart valve, the newest product in the Company's "gold standard" line of mechanical heart valves.
Maintaining the fundamental features found in St. Jude Medical's industry-leading mechanical heart valve products, the SJM Regent(TM) heart valve offers exceptional structural integrity, durability and low complication rates.
The SJM Regent(TM) aortic heart valve features subtle design modifications to the valve's pyrolytic carbon components, resulting in unprecedented hemodynamic performance. This translates into single-digit pressure gradients - even in valves as small as 19 mm.
"Our experience with the SJM Regent(TM) heart valve has demonstrated a new standard for hemodynamic performance," said Dr. Marc Sakwa, principal investigator at William Beaumont Hospital in Royal Oak, Michigan, the leading U.S. medical center for the SJM Regent(TM) heart valve clinical trials. "The outstanding hemodynamics resulted in a significant reduction of left ventricular (LV) mass in our patients. We believe this will contribute to better survival and improved long-term patient outcomes."
The SJM Regent(TM) heart valve has been marketed in Europe and Canada since 1999. Due to strong customer demand, this valve now makes up a significant percentage of St. Jude Medical's aortic valve sales mix in the international markets where it is available.
St. Jude Medical Gains FDA Approval For Next-Generation Mechanical Heart Valve
ST. PAUL, Minn.--(BUSINESS WIRE)--March 5, 2002--St. Jude Medical, Inc. (NYSE:STJ) today announced it has received U.S. Food and Drug Administration (FDA) approval for the SJM Regent(TM)heart valve, the newest product in the Company's "gold standard" line of mechanical heart valves.
Maintaining the fundamental features found in St. Jude Medical's industry-leading mechanical heart valve products, the SJM Regent(TM) heart valve offers exceptional structural integrity, durability and low complication rates.
The SJM Regent(TM) aortic heart valve features subtle design modifications to the valve's pyrolytic carbon components, resulting in unprecedented hemodynamic performance. This translates into single-digit pressure gradients - even in valves as small as 19 mm.
"Our experience with the SJM Regent(TM) heart valve has demonstrated a new standard for hemodynamic performance," said Dr. Marc Sakwa, principal investigator at William Beaumont Hospital in Royal Oak, Michigan, the leading U.S. medical center for the SJM Regent(TM) heart valve clinical trials. "The outstanding hemodynamics resulted in a significant reduction of left ventricular (LV) mass in our patients. We believe this will contribute to better survival and improved long-term patient outcomes."
The SJM Regent(TM) heart valve has been marketed in Europe and Canada since 1999. Due to strong customer demand, this valve now makes up a significant percentage of St. Jude Medical's aortic valve sales mix in the international markets where it is available.